Palvella Therapeutics (PVLA) Interest Expenses (2014 - 2024)

Palvella Therapeutics (PVLA) has reported Interest Expenses for 14 consecutive years, with $314.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest Expenses rose 714.25% year-over-year to $314.3 million; the TTM figure through Mar 2026 stood at $314.3 million (up 714.25% YoY), while the FY2025 annual figure was $131.2 million, up 40.62% from the prior year.
• Interest Expenses improved to $314.3 million in Q1 2026 per PVLA's latest filing, from $38.6 million in the prior quarter.
• Across five years, Interest Expenses topped out at $314.3 million in Q1 2026 and bottomed at -$1.6 million in Q4 2023.
• Historically, Interest Expenses has averaged $27.4 million across 5 years, with a median of $500000.0 in 2022.
• Annual changes were most pronounced in 2023 — Interest Expenses plunged 300.0% — and 2026, when it surged 714.25%.
• Palvella Therapeutics' Interest Expenses stood at $800000.0 in 2022, then slumped by 300.0% to -$1.6 million in 2023, then jumped by 111.31% to $181000.0 in 2024, then surged by 21225.97% to $38.6 million in 2025, then soared by 714.25% to $314.3 million in 2026.
• Business Quant data shows PVLA's Interest Expenses at $314.3 million in Q1 2026, $38.6 million in Q1 2025, and $181000.0 in Q4 2024.